THE FUTURE OF GLOBAL HEALTHCARE
We live in a post-genomic era, where data, molecular engineering, and new frameworks redefine possibilities. Researchers, engineers, and biotech firms are moving beyond the “nature-inspired” paradigm. The lines between biology, engineering, nanotech, and IT are becoming increasingly blurred. What we’re seeing here isn’t just gradual iteration. It’s a revolution, a mass convergence of multiple different fields: Bioconvergence.
What does this mean for the healthcare industry? Researchers recognized that biology wasn’t just a source of challenges. Wedded to technology, it offered real solutions. Molecular engineers, medical scientists, and biologists came together and a new paradigm was born: Bioconvergence.
What is Bio Convergence?
The new frontier in healthcare
Over the past century, we’ve made immense strides in tackling infectious diseases like smallpox, influenza, polio, and now lately, COVID-19. Over the past 30 years, advancements in HIV/AIDS therapy have saved millions of people, with retroviral treatments allowing people to live out full lives.
However, despite massive investment and research effort, less progress has been made to tackle chronic illnesses like cancer, heart disease, and chronic organ failure. What’s behind this discrepancy? Individual factors. When it comes to chronic disease, no two people have the same experience. The causes are different, comorbidities can differ, and access to care can vary because of the cost and demand to convention treatment regimens.
Conventional treatments like chemotherapy have saved countless lives over the past decades, and iterative improvements and refinements have enabled progressively better outcomes. However, there is more that could be done.
Omics-based profiling helps doctors identify specific mutations and biomarkers in a tumor, letting them narrow down effective treatment options. Miniaturized drug delivery delivers medication to specific cancer-affected areas, without damaging the surrounding tissue. And once the tumor has been successfully removed, bioconvergence makes complete tissue replacement a reality.
Although bioconvergence as a school of thought has been around for quite a while, high costs and turnaround time have limited the success of bioconvergence-based treatments in the market, until recently.
Related developments like next-generation DNA sequencing now help to bring down cost and turnaround time on bioconvergence-based treatment approaches. Sequencing helps doctors identify underlying genetic risk factors. It also allows researchers to rapidly identify different types of cancers and pathogens.
Bio Convergence as an industry
Bioconvergence is a major step forward for allied industries like biotech, life sciences, and even robotics. It is transforming the research and development infrastructure that’s responsible for many of this decade’s healthcare innovations.
At an industry level, bioconvergence solves a fundamental problem every biotech firm faces: Bridging the gap between molecular engineering expertise and biology.
This has a real impact on procurement and budget allocation. Engineers who actually operate (and troubleshoot!) laboratory technologies have an entirely different set of expectations and needs compared to research teams. At BICO, we’ve made bioconvergence a priority in order to bridge this gap, enabling flexibility and greater efficiency.
Bioconvergence is the future of healthcare, a future that promises targeted, personalized treatment, cures for illnesses, and hope for better, more accessible care worldwide. By integrating biology research with engineering expertise, by recognizing that these are two sides to the same coin, BICO, as the leading bioconvergence company, is pushing the industry forward and helping create the future of medicine.